​

EyePoint Pharmaceuticals (EYPT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

EYPT Stock Forecast

EyePoint Pharmaceuticals (EYPT) stock forecast, based on 6 Wall Street analysts, predicts a 12-month average price target of $22.00, with a high of $22.00 and a low of $22.00. This represents a 182.05% increase from the last price of $7.80.

$5 $10 $15 $20 $25 $30 High: $22 Avg: $22 Low: $22 Last Closed Price: $7.8

EYPT Stock Rating

EyePoint Pharmaceuticals stock's rating consensus is Buy, based on 6 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 6 0 6 Strong Sell Sell Hold Buy Strong Buy

EYPT Price Target Upside V Benchmarks

TypeNameUpside
StockEyePoint Pharmaceuticals182.05%
SectorHealthcare Stocks 25.00%
IndustryBiotech Stocks 63.52%

Price Target Trends

1M3M12M
# Anlaysts-13
Avg Price Target-$22.00$27.33
Last Closing Price$7.80$7.80$7.80
Upside/Downside-182.05%250.38%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Feb, 2548---12
Jan, 2549---13
Dec, 2448---12
Nov, 2449---13
Oct, 2449---13
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 11, 2024Yi ChenH.C. Wainwright$22.00$11.5989.82%182.05%
May 13, 2024Yi ChenH.C. Wainwright$30.00$12.17146.51%284.62%
May 07, 2024Graig SuvannavejhMizuho Securities$30.00$11.20167.86%284.62%
Aug 04, 2022H.C. Wainwright$25.00$10.22144.62%220.51%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 28, 2024GuggenheimBuyBuyhold
Oct 28, 2024LaidlawBuyBuyhold
Aug 28, 2024JefferiesBuyinitialise
Aug 13, 2024Chardan CapitalUnderperformUnderperformhold
Jun 27, 2024H.C. WainwrightBuyBuyhold
Jun 26, 2024LaidlawBuyBuyhold
May 13, 2024H.C. WainwrightBuyBuyhold
May 07, 2024Chardan CapitalUnderperformUnderperformhold
Mar 08, 2024H.C. WainwrightBuyBuyhold
Nov 11, 2022GuggenheimBuyBuyhold

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 $1 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-4.10$-2.22$-3.34$-1.82-----
Avg Forecast$-1.82$-1.95$-2.19$-1.94$-2.17$-2.51$-2.82$-2.42$0.11
High Forecast$-2.74$-2.94$-3.48$-2.16$-2.31$-3.04$-3.27$-3.45$0.01
Low Forecast$-0.80$-0.86$-1.18$-1.80$-1.86$-2.05$-2.26$-1.37$0.22
Surprise %125.27%13.85%52.51%-6.19%-----

Revenue Forecast

$0 $120M $240M $360M $480M $600M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$34.44M$36.94M$41.40M$46.02M-----
Avg Forecast$45.60M$35.19M$41.28M$40.74M$42.56M$17.58M$12.48M$58.91M$310.06M
High Forecast$25.97M$20.04M$26.63M$32.38M$37.34M$5.18M$12.48M$57.38M$91.30M
Low Forecast$63.34M$48.88M$60.17M$45.92M$53.22M$31.73M$12.48M$60.44M$559.56M
Surprise %-24.47%4.97%0.31%12.96%-----

Net Income Forecast

$-150M $-110M $-70M $-30M $10M $50M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-52.65M$-63.91M$-124.51M$-70.80M-----
Avg Forecast$-70.81M$-76.02M$-61.30M$-70.80M$-80.95M$-99.07M$-107.54M$-93.87M$4.12M
High Forecast$-106.62M$-114.47M$-73.56M$-84.95M$-89.68M$-118.26M$-127.06M$-134.38M$341.29K
Low Forecast$-31.18M$-33.47M$-49.04M$-56.64M$-72.22M$-79.87M$-88.02M$-53.36M$8.43M
Surprise %-25.64%-15.92%103.12%------

EYPT Forecast FAQ

Is EyePoint Pharmaceuticals stock a buy?

EyePoint Pharmaceuticals stock has a consensus rating of Buy, based on 6 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that EyePoint Pharmaceuticals is a favorable investment for most analysts.

What is EyePoint Pharmaceuticals's price target?

EyePoint Pharmaceuticals's price target, set by 6 Wall Street analysts, averages $22 over the next 12 months. The price target range spans from $22 at the low end to $22 at the high end, suggesting a potential 182.05% change from the previous closing price of $7.8.

How does EyePoint Pharmaceuticals stock forecast compare to its benchmarks?

EyePoint Pharmaceuticals's stock forecast shows a 182.05% upside, outperforming the average forecast for the healthcare stocks sector (25.00%) and outperforming the biotech stocks industry (63.52%).

What is the breakdown of analyst ratings for EyePoint Pharmaceuticals over the past three months?

  • February 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • January 2025: 30.77% Strong Buy, 69.23% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is EyePoint Pharmaceuticals’s EPS forecast?

EyePoint Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December is $-2.17 for 2024, a 19.23% increase from the reported $-1.82 in 2023. The prediction for 2025 is $-2.51, $-2.82 for 2026, $-2.42 for 2027, and $0.11 for 2028.

What is EyePoint Pharmaceuticals’s revenue forecast?

EyePoint Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December is $42.56M for 2024, a -7.52% decrease from the reported $46.02M in 2023. The forecast for 2025 is $17.58M, $12.48M for 2026, $58.91M for 2027, and $310.06M for 2028.

What is EyePoint Pharmaceuticals’s net income forecast?

For its fiscal year ending in December, EyePoint Pharmaceuticals's average annual net income forecast is $-80.949M for 2024, reflecting an 14.34% increase from the reported $-70.795M in 2023. The projection for 2025 is $-99.065M, $-108M for 2026, $-93.87M for 2027, and $4.12M for 2028.